Oxurion Valuation

Is OXUR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OXUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OXUR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OXUR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OXUR?

Key metric: As OXUR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OXUR. This is calculated by dividing OXUR's market cap by their current revenue.
What is OXUR's PS Ratio?
PS Ratio	5.1x
Sales	€84.00k
Market Cap	€427.60k

OXUR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	145.5x
Enterprise Value/EBITDA	-1.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does OXUR's PS Ratio compare to its peers?

The above table shows the PS ratio for OXUR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.8x
BIOS BioSenic	0.6x	n/a	€1.7m
WAVE Waverley Pharma	5.6x	n/a	CA$540.0k
ALEMS European Medical Solutions	0.6x	n/a	€28.3m
ALVET TheraVet	0.3x	n/a	€285.5k
OXUR Oxurion	5.1x	n/a	€427.6k

Price-To-Sales vs Peers: OXUR is expensive based on its Price-To-Sales Ratio (5.1x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does OXUR's PS Ratio compare vs other companies in the European Biotechs Industry?

38 Companies	Price / Sales	Estimated Growth	Market Cap

38 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: OXUR is good value based on its Price-To-Sales Ratio (5.1x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is OXUR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OXUR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate OXUR's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.